Literature DB >> 19640916

Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease.

Peter Heider1, Jaroslav Pelisek, Holger Poppert, Hans-Henning Eckstein.   

Abstract

OBJECTIVE: Relevant soluble matrix metalloproteinases (MMPs), their inhibitors, tissue inhibitor of metalloproteinases (TIMPs), and serological factors were analyzed as possible biomarkers for neurological symptoms in patients with carotid artery stenosis. METHODS AND
RESULTS: Asymptomatic (n = 76) and symptomatic (n = 69) patients were evaluated. Serum levels of collagenases (MMP-1, -8), gelatinases (MMP-2, -9), stromelysin (MMP-3), matrilysin (MMP-7), and TIMP-1, -2 were determined by enzyme-linked immunosorbant assay (ELISA). Furthermore, fibrinogen, C-reactive protein (CRP), leukocytes, and further serological parameters were measured. Circulating MMP-7, -8, -9, and TIMP-1 were significantly enhanced in symptomatic individuals with P < .001 for MMP-7 and P < .05 for MMP-8, -9, and TIMP-1. Significant correlations were found between various MMPs with highest correlation coefficient of r = .749 between MMP-8 and -9. In addition, MMP-1, -3, -7, -9 correlated significantly with leukocytes, MMP-1, and TIMP-1 with thrombocytes, MMP-8 with fibrinogen, and MMP-7 with creatinine. Combination of more than one biomarker led to significantly enhanced positive predictive value (PPV) for neurological symptom compared to single MMP (MMP-7 + MMP-9: PPV = 73.1%, MMP-7 + MMP-8 + MMP-9: PPV = 73.8% vs. PPV = 62.5%; P < .001).
CONCLUSIONS: Thus, using appropriate analytical approaches, we showed for the first time the possibility to use set of relevant biomarkers as predictors of neurological symptoms. Such biomarkers together with current diagnostic techniques may further contribute to recognize vulnerable lesions to define patients at risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19640916     DOI: 10.1177/1538574409334826

Source DB:  PubMed          Journal:  Vasc Endovascular Surg        ISSN: 1538-5744            Impact factor:   1.089


  7 in total

1.  Plasma levels of matrix metalloproteinase-8 in patients with carotid atherosclerosis.

Authors:  Tamara Djurić; Maja Zivković; Aleksandra Stanković; Ana Kolaković; Djole Jekić; Vesna Selaković; Dragan Alavantić
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Adhesion molecule CD146 and its soluble form correlate well with carotid atherosclerosis and plaque instability.

Authors:  Yi-Ning Qian; Yong-Ting Luo; Hong-Xia Duan; Li-Qun Feng; Qi Bi; Yong-Jun Wang; Xi-Yun Yan
Journal:  CNS Neurosci Ther       Date:  2014-02-24       Impact factor: 5.243

3.  Evaluation of serum biomarkers for patients at increased risk of stroke.

Authors:  Pelisek Jaroslav; Reeps Christian; Ockert Stefan; Zimmermann Alexander; Peter Zepper; Poppert Holger; Eckstein Hans-Henning
Journal:  Int J Vasc Med       Date:  2012-03-15

4.  Hydrocortisone supresses inflammatory activity of metalloproteinase-8 in carotid plaque.

Authors:  Sthefano Atique Gabriel; Leila Antonangelo; Vera Luiza Capelozzi; Camila Baumann Beteli; Otacílio de Camargo Júnior; José Luis Braga de Aquino; Roberto Augusto Caffaro
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jul-Sep

5.  The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice.

Authors:  Petros Moustardas; Nikolaos P E Kadoglou; Michalis Katsimpoulas; Alkistis Kapelouzou; Nikolaos Kostomitsopoulos; Panayotis E Karayannacos; Alkiviadis Kostakis; Christos D Liapis
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

Review 6.  Vulnerable Plaque, Characteristics, Detection, and Potential Therapies.

Authors:  Anouar Hafiane
Journal:  J Cardiovasc Dev Dis       Date:  2019-07-27

7.  The TAXINOMISIS Project: A multidisciplinary approach for the development of a new risk stratification model for patients with asymptomatic carotid artery stenosis.

Authors:  Nathalie Timmerman; George Galyfos; Fragiska Sigala; Kalliopi Thanopoulou; Gert J de Borst; Lazar Davidovic; Hans-Henning Eckstein; Nenad Filipovic; Roberto Grugni; Michael Kallmayer; Dominique P V de Kleijn; Igor Koncar; Michalis D Mantzaris; Elisabeth Marchal; Miltiadis Matsagkas; Perica Mutavdzic; Domenico Palombo; Gerard Pasterkamp; Vassiliki T Potsika; Evangelos Andreakos; Dimitrios I Fotiadis
Journal:  Eur J Clin Invest       Date:  2020-10-02       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.